Prostate-specific antigen is a protein produced by prostate cells. Elevated levels can reflect prostate enlargement (BPH), inflammation, or cancer. PSA is both a screening and tracking marker, though its use for population screening remains debated.
Rising PSA over time is often more meaningful than any single value. PSA velocity, PSA density, and free-to-total PSA ratio add specificity when absolute PSA is borderline. Men considering active surveillance or tracking treatment response rely on PSA trends closely.
Optimal PSA: 0-1.5 ng/mL.
Typically re-tested every 52 weeks.
PSA is an enzyme produced by the epithelial cells lining the prostate's ducts, and its real work happens in semen rather than in blood.
It belongs to the kallikrein family of serine proteases and is also known as kallikrein-related peptidase 3. Prostate cells secrete it into seminal fluid, where it digests the proteins that make freshly ejaculated semen gel-like, liquefying it so sperm can move[1]. Only a tiny fraction of that PSA crosses into the circulation, which is why blood levels are reported in nanograms per millilitre while concentrations in semen are vastly higher. Anything that disturbs the barrier between prostate ducts and nearby blood vessels, whether that is tissue growth, inflammation, pressure or physical trauma, allows more PSA to leak into the bloodstream.
Once in blood, PSA does not circulate as a single uniform molecule. Part of it travels unbound, usually called free PSA, and most of it is bound to protease inhibitors such as alpha-1-antichymotrypsin, usually called complexed PSA. A standard test reports total PSA, the sum of both, and some laboratories can report the free fraction separately because the balance between these forms differs between benign and malignant prostate tissue[2].
The single most useful thing to understand about this marker is in its name. PSA is prostate-specific, not cancer-specific. A raised value tells you the prostate is releasing more protein than expected. It does not tell you why.
PSA matters because it is the main blood-based window into prostate tissue activity, and the prostate is one of the few organs that routinely changes in size and behaviour across a man's second half of life.
In practice the test is used in three different ways. The first is screening, where a blood level is used as an early signal that further evaluation may be worthwhile. The second is monitoring benign conditions such as an enlarging prostate, where the number tracks alongside symptoms. The third is follow-up after prostate cancer treatment, where a rising value after surgery or radiation is the earliest measurable sign of returning disease and is handled under agreed clinical definitions of biochemical relapse[3].
Screening is the use that generates the most debate, and honestly so. Population testing detects prostate cancers earlier than symptoms would, but it also detects slow-growing disease that may never have caused harm, which carries its own cost in biopsies, anxiety and treatment side effects[4]. That tension is why guidance has shifted over the years from blanket testing toward a shared decision between a man and his clinician, weighing age, family history, ethnicity and personal preference[5]. The European and wider literature reached similar conclusions, that the test is informative but needs interpreting in context rather than as a pass or fail line[6].
For someone tracking their own biology over years, the long-term value of PSA is less about one threshold and more about establishing a personal baseline in midlife and watching how it moves. A stable low number over several years is a different piece of information from the same number reached after a steady climb.
Most laboratories treat a total PSA below 4 ng/mL as within their reference range, while FitScript's optimal range sits lower.
| Measure | Typical lab reference range | FitScript optimal range |
|---|---|---|
| Total PSA (serum) | 0 to 4 ng/mL | 0 to 1.5 ng/mL |
PSA rises with age. In 86,728 men at health screening, the 95th percentile climbed from 1.40 ng/mL at 40 and under to 11.31 ng/mL above 80.[13]
| Sex | Age | Upper limit, 95th percentile (ng/mL) |
|---|---|---|
| Men | 40 and under | Up to 1.40 |
| Men | 41 to 50 | Up to 1.70 |
| Men | 51 to 60 | Up to 3.10 |
| Men | 61 to 70 | Up to 5.80 |
| Men | 71 to 80 | Up to 8.82 |
| Men | Over 80 | Up to 11.31 |
These are upper limits in one population, not cancer cut-offs. A PSA result is interpreted with a clinician alongside age, prior results and other findings.
Typical lab reference ranges vary by laboratory, age and sex, and different assays can return slightly different numbers from the same sample. FitScript's optimal range is an optimization target, not a diagnostic cut-off, and no lab value on its own identifies or excludes disease.
Two points of context help here. PSA tends to drift upward with age as prostate volume increases, so a value that is unremarkable in a man in his seventies may deserve a closer look in a man in his forties. And because the protein comes from prostate tissue, PSA is a marker reported for men; it is not part of routine testing for women, and no separate female range applies. The test is also not a yes or no instrument. Clinicians often look at supporting measures such as the free to total ratio, PSA density relative to prostate volume, and the rate of change over time, because these refine what a borderline number is likely to represent[1].
A high PSA means more of the protein is reaching your blood than expected, and the most common explanations are benign.
What people notice. PSA itself produces no symptoms. What men often report alongside a raised value are urinary changes, a weaker or interrupted stream, waking at night to urinate, urgency, incomplete emptying, or discomfort in the pelvis, perineum or on ejaculation. Fever, chills, burning on urination or an inability to pass urine are different in character and are worth discussing with a clinician promptly rather than waiting for a repeat blood draw.
Common causes. Benign prostatic hyperplasia, the age-related enlargement of the gland, is a frequent reason, simply because more prostate tissue releases more PSA. Prostatitis and urinary tract infection raise it through inflammation, sometimes sharply and temporarily. Prostatic calculi, small stones within the gland, have also been associated with inflammation and altered PSA values[7]. Mechanical causes matter too, including recent ejaculation, a recent digital rectal examination, catheterisation, cystoscopy or a recent biopsy. Prostate cancer is on the list, and it is the reason the test exists, but it is one possible explanation among several.
What it means longer term. A single elevated result usually leads to a repeat test after an interval, because transient causes resolve and because assay variability is real. If the value stays up, further evaluation may include free PSA, imaging, or a biopsy decision made with a urologist. A persistently rising PSA after a biopsy that found nothing is a recognised clinical situation with its own management pathway, not a dead end[8]. The sensible reading of a high result is that it is suboptimal and unexplained until someone qualified explains it, never that it should be ignored.
A low PSA usually reflects a small, quiet prostate releasing very little protein into the blood, and in most cases it is unremarkable.
What people notice. Nothing. There is no symptom set attached to a low PSA, and a low value is not associated with poor prostate function, reduced fertility or low testosterone. Men with low values who have urinary symptoms still have those symptoms for other reasons, which is the point worth holding onto.
Common causes. Younger age and smaller prostate volume are the ordinary explanations. Medication is the other big one. Drugs that block the conversion of testosterone to dihydrotestosterone, the 5-alpha-reductase inhibitors prescribed for prostate enlargement or hair loss, shrink prostate tissue and measurably lower PSA, which is why clinicians adjust their interpretation for men taking them. A licensed provider evaluates whether any such medication is appropriate in the first place. Therapies that lower androgen levels have a similar suppressive effect.
What it means longer term. A low result is reassuring but not absolute. Some prostate cancers produce relatively little PSA, so a value inside the reference range does not exclude disease, and that limitation is one of the reasons researchers continue to test additional markers in men without a diagnosis[9]. The practical rule is that symptoms deserve evaluation on their own merit, whatever the number says, and that a low PSA on a 5-alpha-reductase inhibitor should always be interpreted with that medication in view.
More things change a PSA result than most people expect, which is why timing and consistency matter as much as the value itself.
PSA is measured on a standard serum blood draw, and within FitScript it sits inside broad, repeated lab testing rather than a one-off check.
The membership is built around 150+ biomarkers tested per year, which means a marker like PSA is not read once and filed. It is read against your own previous values, alongside the hormones that influence prostate tissue and the inflammatory markers that can explain a temporary spike. Atlas, FitScript's AI health advisor, interprets the result in that context and writes it into your FitScript, so the output is observation first, then what it may reflect, then what is worth raising with a clinician.
That framing matters for a marker this nuanced. Biomarkers earn their clinical value through validation and careful interpretation rather than through a single cut-off applied to everyone[10]. In practice the useful questions are whether the value is stable, whether anything in the weeks before the draw could have inflated it, and whether a repeat under cleaner conditions reproduces it. Where a result warrants medical evaluation, or where a prescription therapy is being considered, a licensed provider reviews the member and decides what, if anything, is appropriate. Nothing here replaces that review.
PSA is best read next to the hormones that drive prostate tissue growth, because they explain much of its natural variation.
The androgen pathway comes first. Testosterone Total gives the overall circulating supply, while Testosterone Free reflects the unbound fraction available to tissue, and the two can diverge considerably. Dihydrotestosterone is the more potent androgen converted from testosterone inside prostate tissue, which is exactly the step that 5-alpha-reductase inhibitors block, so it is the marker that most directly connects to medication-related PSA suppression. SHBG determines how much of your testosterone is bound and therefore unavailable, and shifts in it change free hormone levels without changing the total. DHEA-S tracks adrenal androgen output, an upstream contributor to the same pool. IGF-1 sits in the growth signalling axis. Running these together as part of hormone lab panels such as the Hormone Panel for him is far more informative than a solitary PSA value.
Beyond the standard panel, research continues on additional circulating and urinary markers intended to separate clinically significant disease from the indolent kind that PSA alone cannot distinguish[11], and several candidate blood-based markers have been studied for exactly that purpose[12]. Which of these, if any, belongs in an individual workup is a clinical decision, not a self-serve one.
Treat one PSA value as a data point and the trend as the signal. If your result sits above the laboratory range, avoid drawing conclusions from it, note anything in the preceding days that could have raised it, and arrange a repeat under clean conditions. If it is high with fever, pain or difficulty urinating, that combination is worth discussing with a clinician promptly. If it is low, keep taking symptoms seriously on their own terms, and make sure anyone interpreting the number knows about medications that suppress it. Establishing a baseline in midlife and retesting at the same laboratory is the single most useful habit, because it converts an ambiguous number into a readable line.
This article is educational and is not medical advice. Discuss your results, and any treatment you are considering, with a clinician or licensed provider who can evaluate your full history.
PSA stands for prostate-specific antigen. It is an enzyme made by the prostate that liquefies semen, and only a small amount of it leaks into the blood, which is what a PSA blood test measures in ng/mL.
Not on its own. PSA is prostate-specific, not cancer-specific, and the most common reasons for a raised value are benign, including prostate enlargement, prostatitis, urinary infection, recent ejaculation or a recent examination of the prostate. A result outside the range is suboptimal and unexplained, not diagnostic, and it is worth discussing with a clinician who can decide whether a repeat test or further evaluation is appropriate.
Most laboratories use a total PSA below 4 ng/mL as their reference range, and FitScript's optimal range is 0 to 1.5 ng/mL. Typical lab ranges vary by laboratory, age and sex, and FitScript's optimal range is an optimization target rather than a diagnostic cut-off.
Yes. Some prostate cancers release relatively little PSA, so a value inside the reference range lowers the likelihood of disease but does not exclude it. That limitation is one of the reasons researchers keep studying additional markers, and it is why urinary or other symptoms deserve evaluation regardless of the number.
It can. Recent ejaculation may transiently raise total PSA, which is why many laboratories ask men to avoid it for a day or two before the blood draw. Vigorous cycling, horse riding, a digital rectal examination, catheterisation and a recent biopsy can also raise the value temporarily.
Medications that block the conversion of testosterone to dihydrotestosterone, known as 5-alpha-reductase inhibitors, shrink prostate tissue and measurably lower PSA. Clinicians account for that when interpreting results, so always tell whoever reads your labs that you take one. A licensed provider evaluates whether any such medication is appropriate for you.
PSA circulates partly unbound, called free PSA, and partly bound to protease inhibitors, called complexed PSA. A standard test reports the total of both. The proportion that is free differs between benign and malignant prostate tissue, so the free to total ratio is sometimes used to refine the interpretation of a borderline result.
There is no single interval that suits everyone, and the right frequency depends on your age, family history, symptoms, medications and previous values, which is a decision to make with a clinician. What helps in every case is using the same laboratory each time, since assays differ and a consistent trend is far more informative than isolated numbers.
It may raise PSA in some men, which is one reason providers monitor the marker during treatment. Testosterone therapy is a prescription treatment, and a licensed provider evaluates whether it is appropriate and how it should be monitored.
Total and free testosterone, dihydrotestosterone, SHBG, DHEA-S and IGF-1 all relate to the hormone signalling that influences prostate tissue, so reading them alongside PSA gives far more context than a solitary value. FitScript tests 150+ biomarkers per year, and Atlas interprets each result against your own previous values.